Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Measurable Residual Disease Response and Prognosis in Treatment-Na?ve Acute Myeloid Leukemia With Venetoclax and Azacitidine.

Pratz KW, Jonas BA, Pullarkat V, Recher C, Schuh AC, Thirman MJ, Garcia JS, DiNardo CD, Vorobyev V, Fracchiolla NS, Yeh SP, Jang JH, Ozcan M, Yamamoto K, Illes A, Zhou Y, Dail M, Chyla B, Potluri J, D?hner H. Measurable Residual Disease Response and Prognosis in Treatment-Na?ve Acute Myeloid Leukemia With Venetoclax and Azacitidine. J Clin Oncol. 2022 03 10; 40(8):855-865.

View in: PubMed

collapse authors with profiles